BOSTON – Researchers at Dana-Farber Cancer Institute and the IRCCS San Raffaele Scientific Institute in Milan have identified a novel genomic signature associated with resistance to therapies in multiple myeloma, a cancer of plasma cells. The findings, published this week, detail a complex interplay between cancer cells and their surrounding microenvironment, offering potential new avenues for treatment development.
The study, led by Kenneth C. Anderson, MD, Kraft Family Professor of Medicine at Harvard Medical School and Director of the LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber, and Giovanni Tonon, of the Functional Genomics of Cancer Unit at the IRCCS San Raffaele Scientific Institute, focused on understanding why some patients with multiple myeloma develop resistance to existing treatments, including targeted and immune therapies. According to the Dana-Farber Cancer Institute website, Dr. Anderson has spent four decades researching multiple myeloma.
Researchers analyzed genomic data from multiple myeloma patients, identifying a specific pattern of gene expression that correlated with treatment failure. This signature involves alterations in genes regulating the interaction between myeloma cells and the bone marrow microenvironment, the complex network of cells and proteins surrounding the cancer. The research suggests that changes within this microenvironment allow myeloma cells to evade the effects of therapy.
“We’ve known for some time that the microenvironment plays a critical role in myeloma progression and drug resistance,” said Dr. Anderson in a statement accompanying the research. “This study provides a deeper understanding of the specific genomic changes that drive this interaction, and identifies potential targets for new therapies.”
The team employed advanced genomic sequencing and computational analysis to identify the key genes and pathways involved in resistance. Their work builds on previous research by Dr. Anderson, who has developed laboratory and animal models of multiple myeloma to identify novel therapeutic targets. The study also involved contributions from researchers at the Ludwig Center at Dana-Farber/Harvard Cancer Center and the Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico in Milan.
The findings highlight the importance of considering the tumor microenvironment when developing treatment strategies for multiple myeloma. The researchers are now working to validate these findings in larger patient cohorts and to develop new therapies that specifically target the identified genomic signature. Further research will focus on translating these discoveries into clinical trials, with the goal of improving outcomes for patients with multiple myeloma.
According to the International Myeloma Society, Dr. Anderson is a past president of the organization and a recipient of numerous awards for his contributions to myeloma research. He also serves as editor-in-chief of the journal Clinical Cancer Research.
The study’s authors have not announced a timeline for the initiation of clinical trials based on these findings. Dana-Farber Cancer Institute and the IRCCS San Raffaele Scientific Institute have not issued further statements regarding the research as of today.
